Overview
Introduction
With the growing interest in the role of inflammation in the pathogenesis of
atherosclerosis and thrombosis, C-reactive protein (CRP) has been looked at with
renewed interest as a marker of coronary artery disease. In January 2003, the
AHA/CDC issued recommendations for high-sensitivity CRP (hs-CRP) testing in the
assessment of patients considered at moderate cardiovascular risk.
Scope
- Provides a clearer view of the current debate surrounding the routine use of
C-reactive protein.
- Outlines the recent AHA/CDC recommendations, including the panel’s review
criteria and research suggestions.
- Assesses the evidence behind the recommendations and the clinical data
relating to CRP testing and the role of inflammation in CV disease.
- Analyzes the likely commercial impact of the new AHA/CDC guidelines and the
increased use of CRP testing.
Report Highlights
There are statistically significant positive correlations between CRP levels
and established cardiovascular risk factors. Furthermore, C-reactive protein has
been shown to be a strong independent marker of cardiovascular risk and has
demonstrated potential in the risk stratification of acute coronary syndrome
patients.
Current cardiovascular therapies have demonstrated CRP-lowering abilities
and/or anti-inflammatory properties suggesting that their effects may be due
more to their anti-inflammatory properties than their conventionally attributed
mechanism of action.
The developing research in the role of inflammation in cardiovascular disease
combined with the increased interest in the anti-inflammatory properties of
existing cardiovascular therapies has interesting implications for the
developmental of future compounds.
Reasons to Purchase
- Assess the evidence and ongoing trials concerning CRP testing and identify
the likely future direction of research.
- Understand the AHA/CDC guidelines and the impact that they will have on
clinical practice and the cardiovascular market.
- Evaluate the potential implications of CRP testing for the development of
both existing and novel cardiovascular drugs.
View Cart
